Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$29.78 USD

29.78
19,547,758

+0.28 (0.95%)

Updated Jul 17, 2024 12:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck's Biosimilar Insulin Gets Tentative FDA Approval

by Zacks Equity Research

Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.

    AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?

    by Zacks Equity Research

    AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.

      HCA Healthcare (HCA) Q2 Earnings: Will it Beat Estimates?

      by Zacks Equity Research

      HCA Healthcare's (HCA) second-quarter earnings are likely to witness equivalent, admission growth and accretion from a number of acquisitions. Commercial business will likely be a dampener.

        Can Merck (MRK) Pull Off a Surprise this Earnings Season?

        by Zacks Equity Research

        Merck & Co., Inc.'s (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q2. However, headwinds remain in the form genericization of key drugs and increasing competition.

          What Lies in Store for Glaxo (GSK) this Earnings Season?

          by Zacks Equity Research

          The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair.

            Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?

            by Zacks Equity Research

            At Biogen's (BIIB) Q2 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in Q2.

              Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?

              by Zacks Equity Research

              Eli Lilly and Company's (LLY) new drugs like Trulicity, Cyramza, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

                Kevin Cook headshot

                4 Healthcare Megatrends for Investors

                by Kevin Cook

                One sector combines the best of science and technology with our dreams for healthier and wealthier lives.

                  J&J (JNJ) Beats on Q2 Earnings, Lags Sales, Ups 2017 View

                  by Zacks Equity Research

                  Johnson & Johnson (JNJ) reported mixed second-quarter 2017 results. While earnings beat expectations, sales missed the same.

                    Paratek Antibiotic Candidate's Phase III Data Favorable

                    by Zacks Equity Research

                    Paratek Pharmaceuticals, Inc. (PRTK) announced positive results from a phase III study (OASIS-2) comparing its antibiotic candidate omadacycline to Pfizer Inc.'s (PFE) Zyvox for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

                      Pfizer Xeljanz Label Expansion Application Accepted by FDA

                      by Zacks Equity Research

                      Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) for Xeljanz has been accepted for review by the FDA.

                        Arpita Dutt headshot

                        Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.

                        by Arpita Dutt

                        Novartis (NVS) was in the limelight this week with its CAR-T cell therapy receiving the support of an FDA advisory panel.

                          Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?

                          by Zacks Equity Research

                          Shares of Exelixis, Inc. (KITE) have gained almost 4.68% on Aug 12. The company's shares have rallied a whopping 77% this year so far, outperforming the 7.8% increase registered by the Zacks categorized industry during this period.

                            Corcept Therapeutics Focuses on Korlym's Label Expansion

                            by Zacks Equity Research

                            We issued an updated research report on Corcept Therapeutics Incorporated (CORT) on Jul 12.

                              Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion

                              by Zacks Equity Research

                              We issued an updated research report on Boulder, CO-based Clovis Oncology, Inc. (CLVS) on Jul 12.

                                Pfizer's Mylotarg Recommended by FDA Advisory Committee

                                by Zacks Equity Research

                                Pfizer Inc. (PFE) announced that the FDA's Oncologic Drug Advisory Committee (ODAC) voted in favor of Mylotarg for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML).

                                  Amgen Gets FDA Nod to Broaden Leukemia Drug Blincyto's Label

                                  by Zacks Equity Research

                                  Amgen Inc. (AMGN) announced that its supplemental biologics license application (sBLA) to convert accelerated approval for leukemia drug Blincyto to regular approval has been approved by the FDA.

                                    J&J (JNJ) to Commence Pharma Q2 Earnings Season: What's Up?

                                    by Zacks Equity Research

                                    Johnson & Johnson (JNJ), a healthcare bellwether, will report second-quarter 2017 results on Jul 18.

                                      Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx

                                      by Zacks Equity Research

                                      Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC.

                                        Arena's Ralinepag Positive in Phase II PAH Study, Shares Up

                                        by Zacks Equity Research

                                        Arena Pharmaceuticals, Inc. (ARNA) shares surged 41.3% in after-market trading on Monday after its phase II study evaluating its key pipeline candidate, ralinepag, in pulmonary arterial hypertension, met the primary endpoint.

                                          Lilly's Breast Cancer Drug Gets Priority Review Status by FDA

                                          by Zacks Equity Research

                                          Eli Lilly and Company (LLY) announced that its new drug application for its pipeline candidate, abemaciclib , has been accepted for priority review by the FDA for patients with advanced breast cancer.

                                            Puma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial

                                            by Zacks Equity Research

                                            Puma Biotechnology, Inc. (PBYI) announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 in combination with Xeloda for treatment of third-line HER2-positive metastatic breast cancer.

                                              Arpita Dutt headshot

                                              Pharma Stock Roundup: MRK's Keytruda MM Combo Studies on Clinical Hold, Bayer to Revise Outlook

                                              by Arpita Dutt

                                              3 studies on Merck's (MRK) Keytruda have been put on clinical hold while Bayer said that it expects to revise its 2017 outlook when it reports Q2 results.

                                                Pfizer's (PFE) Leukemia Candidate Receives Approval in EU

                                                by Zacks Equity Research

                                                Pfizer Inc. (PFE) announced that its leukemia candidate, Besponsa, has been approved by the European Commission.

                                                  Why is Corcept's Stock Up More Than 60% So Far This Year?

                                                  by Zacks Equity Research

                                                  Shares of Corcept Therapeutics Incorporated (CORT) has soared 62.5% this year so far, massively outperforming the 5.6% increase registered by the Zacks classified Medical Drugs industry during this period.